Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07114614 · ClinicalTrials.gov registry record
Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- 120
- Enrollment target
NCT07114614: Recruiting study, sponsored by Case Comprehensive Cancer Center.
NCT07114614 is a clinical trial that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07114614 is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
Study Summary
The purpose of this research study is to investigate whether cancer survivors have higher levels of proteins called Fatty Acid Binding Proteins as well as 12 different markers of cellular senescence than people who have never had cancer. Investigators believe that these levels may be elevated in cancer survivors as a result of their cancer and the treatments they received and may put them at higher risk for chronic conditions such as high cholesterol, diabetes, high blood pressure, and obesity. This study will also compare the levels of these proteins and inflammatory markers in the blood with different aspects of cancer treatment the survivors received. Investigators are investigating if there is a correlation between levels of these proteins and markers, the type of treatment cancer survivors received, and development of metabolic conditions.
Interventions
- OTHER Specimen #1
- OTHER Specimen #2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-07 |
| Est. Completion | 2026-12 |
What NCT07114614 shows while recruiting
NCT07114614 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Specimen #1 is the first listed.
NCT07114614 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07114614 about?
NCT07114614 is a clinical study titled "Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors". The purpose of this research study is to investigate whether cancer survivors have higher levels of proteins called Fatty Acid Binding Proteins as well as 12 different markers of cellular senescence than people who have never had cancer. Investigators believe that these levels may be elevated in can...
What is the current status of trial NCT07114614?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2026-07. Estimated completion is 2026-12.
What interventions are being tested in trial NCT07114614?
The interventions under investigation include: Specimen #1 (OTHER), Specimen #2 (OTHER).
Who is sponsoring clinical trial NCT07114614?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia